
ECTRIMS 2025: Roche Data Reinforces OCREVUS Efficacy and Highlights Fenebrutinib’s Potential in Multiple Sclerosis Treatment
Major MS Data Presented at ECTRIMS: Long-Term OCREVUS Safety Confirmed; Fenebrutinib Phase II Shows Near-Complete Disease Suppression Introduction At the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Roche presented a substantial…

